脊柱关节炎真实世界死亡率:TriNetX全球协作网络证据
OBJECTIVE: To assess all-cause mortality in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and to examine the influence of sex, comorbidities and biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in a large, multinatio…
要点
- axSpA和PsA全因死亡风险均显著高于一般人群,axSpA更高。
- 男性性别与axSpA和PsA死亡率升高相关。
- b/tsDMARDs尤其是TNF抑制剂与axSpA和PsA死亡率降低相关。
核心结论
- axSpA和PsA全因死亡率仍升高,尤其axSpA,男性预后更差,TNF抑制剂治疗与结局改善相关。
研究设计与样本
- 回顾性队列研究,使用TriNetX全球协作网络涵盖超100家医疗机构、逾1.5亿人的匿名电子健康记录。
- 纳入2010至2020年间至少有2次强直性脊柱炎或关节病型银屑病诊断的成人,采用倾向评分匹配校正人口学和合并症。
主要发现
- 与一般人群相比,axSpA死亡风险显著升高(HR 1.71,95%CI 1.61至1.81),PsA亦升高(HR 1.26,95%CI 1.20至1.32)。
- axSpA死亡率较PsA高42%(HR 1.42,95%CI 1.34至1.51)。
- 男性与死亡率升高相关(axSpA HR 1.65;PsA HR 1.26)。
- 与未治疗患者相比,b/tsDMARDs尤其TNF抑制剂使axSpA死亡率降低47%、PsA降低38%。
临床怎么用
- 对axSpA和PsA患者应关注死亡风险,尤其男性,早期靶向管理可能有助于降低死亡率。
- TNF抑制剂治疗与死亡率改善相关,支持在适宜患者中积极使用b/tsDMARDs。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess all-cause mortality in patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA), and to examine the influence of sex, comorbidities and biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in a large, multinational, real-world cohort. METHODS: This retrospective cohort study used the TriNetX Global Collaborative Network, comprising anonymised electronic health records from over 150 million individuals across >100 healthcare organisations worldwide. Adults with ≥2 diagnoses of ankylosing spondylitis or arthropathic psoriasis between 2010 and 2020 were included. Propensity score matching accounted for demographics and comorbidities. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate HRs for all-cause mortality, comparing axSpA and PsA cohorts with each other and with matched general population controls. RESULTS: We identified 32 368 patients with axSpA, 52 402 patients with PsA and 9 742 949 controls. Compared with the general population, mortality risk was significantly higher in axSpA (HR 1.71, 95% CI 1.61 to 1.81) and PsA (HR 1.26, 95% CI 1.20 to 1.32). Mortality was 42% greater in axSpA than PsA (HR 1.42, 95% CI 1.34 to 1.51). Male sex was associated with increased mortality (axSpA HR 1.65; PsA HR 1.26). Treatment with b/tsDMARDs, particularly tumour necrosis factor (TNF) inhibitors, reduced mortality by 47% in axSpA and 38% in PsA compared with untreated patients. CONCLUSION: All-cause mortality remains elevated in axSpA and PsA, particularly in axSpA. Male sex predicts poorer survival, whereas TNF inhibitor therapy is associated with improved outcomes. Early, targeted management may help reduce mortality in spondyloarthritis.
引用
- Llop M, Rodrigo-Parés A, Saus E, et al. Mortality incidence in spondyloarthritis: real-world evidence using the TriNetX Global Collaborative Network. RMD Open. 2026. PMID: 41825927. doi:10.1136/rmdopen-2025-006564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。